Leal T, et al. Identifying resistance to immune checkpoint inhibitors by screening for PD-L1 and MHC I expression on CTCS in pts with NSCLC. IASLC 2018; abstract P3.04-08.
I-SPY2: voordeel van toevoegen pembrolizumab aan neoadjuvante chemotherapie
mrt 2020 | Borstkanker